Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

First published in Diabetes, Obesity and Metabolism on 2014 Mar.
Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19.

Authors: Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC

 

 

 

 

Read more

Download full article as Pdf file:

Pdf File

 

REACHING OUT IS EASY AND FAST – LET’S TALK

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management


LET’S TALK BUSINESS